Meme karsinomlarında S-100, vimentin, sitokeratin ve HMB-45 ekspresyonu

Amaç: Bu çalışmada meme karsinomu olgularında; immün belirleyicilerin ekspresyonu ile tümörlerde histolojik derece ve aksiller lenf nodu metastazı arasındaki korelasyonu araştırmak amaçlanmıştır. Yöntem: 32. invaziv duktal karsinom, 1. invaziv papiller karsinom, 1 invaziv lobüler karsinom ve 1 atipik medüller karsinom olmak üzere toplam 35 meme karsinomu olgusu incelenmiştir. Formalinle fikse edilmiş ve parafine gömülmüş dokulardan alınan kesitlere S-100, vimentin, sitokeratin (56 ve 64Kd molekül ağırlığında poliklonal), HMB-45 immünoperoksidaz yöntemi ile immünohistokimyasal boyama yapılmıştır. Bulgular: Olgularımızda immünohistokimyasal sonuçların dağılımı şöyledir. S-100 16 olguda (% 45.7), Vimentin 13 olguda ( % 37) , Sitokeratin 12 olguda ( % 34), HMB-45 12 olguda (% 34) pozitif olarak tespit edilmiştir. Vimentin ekspresyonu ile histolojik derece ve aksiler lenf nodu metastazı arasında korelasyon izlenmemiştir. Sitokeratin ve S-100 pozitifliği ile histolojik dereceler arasında anlamlı bir fark bulunmazken, bu olgularda lenf nodu metastazının daha az olduğu gözlenmiştir (P

S-100, vimentin, cytokeratin and HMB-45 expression in breast carcinomas

Objective: The aim of this study is to determine the expression of the immunohistochemical markers with recpect to the histologic grade and lymph node metastasis in breast carcinomas. Methods: We studied 35 cases, distributed as 32 invasive ductal carcinoma, 1 invasive papillary carcinoma, 1 invasive lobular carcinoma and 1 atypical medullary carcinoma. Paraffin sections were immonhistochemically stained with S-100, Vimentin, Sitokeratin (6 and 64 kd M.W, polyclonal) and HMB 45 using immunoperoxidase technique. Results: Immunhistochemical results were as follows; S 100 positivity in 16 cases (45,7%) Vimentin positvity in 13 cases (37%) Cytokeratin positivity in 12 cases (34%) and HMB-45 positivity in 12 cases (34%). Vimentin expression exhibited no correlation, between histologic grade and lymph node metastasis. Although there was no significant difference, between Cytokeratin and S-100 positivity with respect to histologic grade. We observed few axillary lymph node metastasis in those cases (P<0.05). We did not observe significant difference between HMB-45 + and &#8211; for histologic grade, but in HMB-45 positive cases more axillary lymph node metastasis were evaluated according to negative cases (P<0.05). Conclusion: While our results with S-100 and Vimentin were in concordance with the literature, we found higher degree of HMB-45 expression compared to the previous reports.

___

  • 1. Leon AS, Gilham P, Milios J. Sitokeratin and vimentin, intermediate filament pros in benign and neoplastik prostotik epitelium. Histopathology 1988;13:435-42.
  • 2. Altransbeser M, Dralle H, Weber K, Osborn. Needle aspirates by means of monoclonal antibodies. Acta Cytol 1986;30:214- 24.
  • 3. Osborn M, Weber K. Biology of diease tumour diagnosis by intermediate filament typing a novel tool for surgical pathology. Lab Invest 1983;48:372-93.
  • 4. Acs G, Simpson JF, Bleiweiss IJ, Hugh J, Reynolds C, Olson S, Page DL. Microglandular adenosis with transition into adenoid cystic carcinoma of the breast. Am J Surg Pathol 2003;27:1052-60.
  • 5. Ryska A, Reynolds C, Keeney GL. Benign tumors of the breast with multinucleated stromal giant cells. Immunohistochemical analysis of six cases and review of the literature. Virchows Arch 2001;439:768-75.
  • 6. Yombe H. İshii Y. Tabuchi K, Isabe T, Kikuchi K. Detection of S-100 protein in melanocytic and neurogenic cutaneus tumors. Arch Dermatol Res 1984; 276:160-4.
  • 7. Egan MJ, Neva J, Crocher J, Collard M. İmmunohistokimyasal localization of S-100 protein in benign and malignant conditons of breast. Arch Pathol Lab Med 1987:111:28-31.
  • 8. Nahojimo T, Watanabe S, Sato Y, Kaveya T, Hirota T, Shimosato Y. Immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 1982;6:715-27.
  • 9. Duarakanath S, Lee AKC, Delellis RA, Silverman ML, Frasca L, Walfe HJ. S-100 protein positivity in breast carcinomas: A potential pitfall in diagnostic immunohistochemistry. Hum Pathol 1987;18:1144-8.
  • 10. Hirayama K, Honda Y, Sako T, Okamoto M, Tsunoda N, Tagami M, et al. Invasive ductal carcinoma of the mammary gland in a mare. Vet Pathol 2003;40:86-91.
  • 11. Lunde S, Nesland JM, Holu R, Johannessen JV. Breast carcinomas with protein S-100 immunoreactivity: An immunohistochemical and ultrastructural study. Pathol Res Proct 1987;182: 627-62.
  • 12. Gillet CE, Bobrow LG, Millis RR. S-100 protein in human mammary tıssue–immunoreactivity in breast carcinoma, including Paget’s Disease of the nipple, and value as a marker of myoepithelial cells. J Pathol 1990;160:19-24.
  • 13. Nakajima T, Watanabe S, Sato Y, Kameye T, Hirota T, Shimosato Y. An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am Surg Pathol 1982;6:715-727.
  • 14. Schmit FC, Bacchi CE, S-100 protein: Is it useful as a tumour marker in diagnosic immunohistochemistry? Histopathology 1989;15:281-8.
  • 15. Mat Sushima S, Mori M, Adachi Y, Mutsukuma A, Sugimachi K. S-100 protein positive human breast carcinomas: An immunohistochemical study. T Surg Oncol 1994;5:108-13.
  • 16. Glasgow BJ, Wen D.R, Al-Jitawi S, Cochran AJ. Antibody to S-100 protein aids the separation of pagetiod melanoma from mammary and extramammary Paget’s disease. J Cutan Pathol 1987;14:223-6.
  • 17. Drier JK, Swanson PE, Cherwitz DL, Wick MR. S-100 protein immunoreactivity in poorly differentiated carcinomas. Arch Pathol Lab Med 1987;3:447-52.
  • 18. Nakamura S, Ishida-Yamamoto A, Takahashi H, Hashimoto Y, Yokoo H, Iizuka H. Pigmented Paget's disease of the male breast: Report of a case. Dermatology. 2001;202:134-7.
  • 19. Strbac M, Popovic L, Jovic M, Ilic S, Dimitrijevic J. Breast carcinoma with melanocytic differentiation. Vojnosanit Pregl 2002;59(6 Suppl):99-102.
  • 20. Brasanac D, Boricic I, Todorovic V. Epidermotropic metastases from breast carcinoma showing different clinical and histopathological features on the trunk and on the scalp in a single patient. J Cutan Pathol 2003;30:641-6.
  • 21. Essa TM, El Tatawi FA, Hamdi KN, Arafawa. Vimentin expression in different types of breast carcinoma: An immunohistochemical study. J Egypt Soc Parasitol 1996;26: 433-42.
  • 22. Heatley M, Whiteside C, Maxwell P, Toner P. Vimentin expression in benign and malignant breast epithelium. J Clin Pathol 1993;46:441-5.
  • 23. Athanassiadou P, Lazaris D, Petrakak P, Keramopuoulos K, Aravantionos D. Vimentin and alfa fetoprotein experisson in breast cancer smears: Relationship with various prognostic factors. Cancer Detection Prev 1997;21:207-12.
  • 24. Domagala W, Lasota J, Barthowiak J, Weber K, Osborn M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki67 growth fraction. Am J Pathol 1990;136:219-27.
  • 25. Toi M, Nakamura T, Mukaida H, Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 1980;65:1980-4.
  • 26. Schaller G, Fuchs I, Pritze W, Ebert A. Herbts B, Pantel K, et al. Elevated Keratin-18 protein expression indicates a favorable prognosis in patents with breast cancer. Clinical Cancer Res 1996;2:1879-85.
  • 27. Moll R. Cytokeratins as markers of differentiation: Expression profiles in epithelial and non-epithelial tumors. New York: Gustav Fischer; 1993. pp.90-6.
  • 28. Bonetti F, Colombari R, Menfrin E, Zamboni G, Mortifnani G, Mombello A, Chilosi M. Breast carcinoma with positive results for melanoma marker (MHB-45) immunoreactivity in normal and neoplastic breast. A J Clin Pathol 1989:491-5.